TABLE 10. Estimated percent using inhaled short acting beta agonists among adults1 with current2 or active3 asthma status by state/territory – BRFSS Asthma Call-back Survey Land Line Sample, United States, 2011
State/Territory | Current | Active | ||||||
---|---|---|---|---|---|---|---|---|
Sample size± |
% | SE§ | 95% CI† | Sample size |
% | SE | 95% CI | |
Alabama | 192 | 53.5 | 7.3 | (39.2 – 67.8) | 210 | 57.5 | 6.8 | (44.2 – 70.8) |
Arizona | 228 | 53.0 | 7.5 | (38.3 – 67.7) | 249 | 50.8 | 7.2 | (36.7 – 64.9) |
California | 506 | 47.6 | 3.7 | (40.3 – 54.9) | 535 | 47.5 | 3.3 | (41.0 – 54.0) |
Connecticut | 252 | 50.2 | 5.9 | (38.6 – 61.8) | 277 | 47.2 | 5.5 | (36.4 – 58.0) |
District of Columbia | 151 | 49.5 | 7.3 | (35.2 – 63.8) | 169 | 49.0 | 7.0 | (35.3 – 62.7) |
Florida | 367 | 50.9 | 5.8 | (39.5 – 62.3) | 416 | 47.2 | 5.4 | (36.6 – 57.8) |
Georgia | 261 | 31.8 | 6.1 | (19.8 – 43.8) | 270 | 32.3 | 6.0 | (20.5 – 44.1) |
Hawaii | 246 | 43.8 | 6.1 | (31.8 – 55.8) | 257 | 47.3 | 6.0 | (35.5 – 59.1) |
Illinois | 175 | 47.6 | 7.2 | (33.5 – 61.7) | 186 | 47.4 | 6.9 | (33.9 – 60.9) |
Indiana | 330 | 50.9 | 4.5 | (42.1 – 59.7) | 342 | 51.7 | 4.5 | (42.9 – 60.5) |
Iowa | 197 | 61.0 | 6.2 | (48.8 – 73.2) | 206 | 59.9 | 6.1 | (47.9 – 71.9) |
Kansas | 737 | 50.7 | 3.5 | (43.8 – 57.6) | 761 | 51.8 | 3.4 | (45.1 – 58.5) |
Louisiana | 267 | 51.6 | 7.3 | (37.3 – 65.9) | 282 | 47.3 | 7.4 | (32.8 – 61.8) |
Maine | 272 | 63.6 | 5.3 | (53.2 – 74.0) | 295 | 59.1 | 5.2 | (48.9 – 69.3) |
Maryland | 211 | 42.1 | 5.4 | (31.5 – 52.7) | 224 | 41.6 | 5.2 | (31.4 – 51.8) |
Massachusetts | 237 | 46.1 | 6.6 | (33.2 – 59.0) | 249 | 45.5 | 6.4 | (33.0 – 58.0) |
Michigan | 498 | 64.2 | 4.1 | (56.2 – 72.2) | 544 | 60.9 | 4.0 | (53.1 – 68.7) |
Mississippi | 262 | 40.2 | 6.0 | (28.4 – 52.0) | 278 | 41.7 | 5.8 | (30.3 – 53.1) |
Missouri | 218 | 59.7 | 6.3 | (47.4 – 72.0) | 221 | 59.4 | 6.5 | (46.7 – 72.1) |
Montana | 340 | 45.5 | 4.6 | (36.5 – 54.5) | 353 | 41.8 | 4.6 | (32.8 – 50.8) |
Nebraska | 665 | 49.6 | 4.1 | (41.6 – 57.6) | 713 | 47.2 | 3.9 | (39.6 – 54.8) |
Nevada | 134 | 63.9 | 8.1 | (48.0 – 79.8) | 141 | 61.9 | 8.1 | (46.0 – 77.8) |
New Hampshire | 222 | 56.5 | 5.7 | (45.3 – 67.7) | 238 | 51.3 | 6.0 | (39.5 – 63.1) |
New Jersey | 343 | 44.6 | 5.0 | (34.8 – 54.4) | 367 | 42.5 | 4.8 | (33.1 – 51.9) |
New Mexico | 316 | 55.6 | 5.5 | (44.8 – 66.4) | 340 | 53.5 | 5.2 | (43.3 – 63.7) |
New York | 135 | 53.5 | 6.8 | (40.2 – 66.8) | 146 | 53.5 | 6.2 | (41.3 – 65.7) |
North Carolina | 229 | 51.0 | 5.7 | (39.8 – 62.2) | 241 | 52.4 | 5.6 | (41.4 – 63.4) |
North Dakota | 176 | 53.9 | 7.4 | (39.4 – 68.4) | 186 | 53.9 | 7.2 | (39.8 – 68.0) |
Ohio | 325 | 58.1 | 5.8 | (46.7 – 69.5) | 336 | 59.9 | 5.5 | (49.1 – 70.7) |
Oklahoma | 295 | 59.8 | 4.9 | (50.2 – 69.4) | 312 | 62.5 | 4.2 | (54.3 – 70.7) |
Oregon | 183 | 70.9 | 5.3 | (60.5 – 81.3) | 199 | 66.2 | 5.5 | (55.4 – 77.0) |
Pennsylvania | 380 | 47.6 | 4.6 | (38.6 – 56.6) | 412 | 46.8 | 4.3 | (38.4 – 55.2) |
Rhode Island | 248 | 48.9 | 5.4 | (38.3 – 59.5) | 270 | 45.1 | 5.2 | (34.9 – 55.3) |
Texas | 521 | 53.2 | 4.6 | (44.2 – 62.2) | 570 | 53.0 | 4.1 | (45.0 – 61.0) |
Utah | 410 | 53.8 | 4.6 | (44.8 – 62.8) | 454 | 51.1 | 4.5 | (42.3 – 59.9) |
Vermont | 306 | 53.4 | 4.5 | (44.6 – 62.2) | 315 | 52.3 | 4.5 | (43.5 – 61.1) |
Washington | 664 | 52.0 | 3.4 | (45.3 – 58.7) | 666 | 53.0 | 3.2 | (46.7 – 59.3) |
West Virginia | 197 | 51.0 | 5.6 | (40.0 – 62.0) | 200 | 51.5 | 5.5 | (40.7 – 62.3) |
Wisconsin | 244 | 56.7 | 6.0 | (44.9 – 68.5) | 244 | 59.0 | 6.1 | (47.0 – 71.0) |
Puerto Rico | 293 | 24.3 | 3.8 | (16.9 – 31.7) | 323 | 23.6 | 3.6 | (16.5 – 30.7) |
40 state total | 12,233 | 50.9 | 1.2 | (48.5 – 53.3) | 12,997 | 50.3 | 1.1 | (48.1 – 52.5) |
Median | 51.3 | 51.4 | ||||||
Range | 24.3-70.9 | 23.6-66.2 |
1 Aged ≥ 18 years
2 “Yes” response to “Do you still have asthma?”
3 Reported any of the following during the past year: asthma medication use, asthma symptoms, or MD visits for asthma
± Landline sample size excludes “DK/Refused”
§ Standard error
† Confidence interval